Annovis Bio Hits 85% Enrollment in Phase 3 Alzheimer's Trial

Annovis Bio (NYSE: ANVS) has reported its first-quarter 2026 business and financial results, showcasing significant progress in its neurodegenerative disease programs. The company announced 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and has closed enrollment to new participants after achieving sufficient screening levels to meet its goals. This milestone brings Annovis closer to potential regulatory submission for its lead drug candidate, buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43. By targeting the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases.

In addition to the Alzheimer’s trial progress, Annovis reported advancements in its Parkinson’s disease open-label extension study, which has reached 40% enrollment. The company is also pursuing new biomarker initiatives and leveraging AI-powered digital monitoring to enhance its research capabilities. These efforts underscore Annovis’s commitment to addressing two of the most challenging neurodegenerative conditions. The company, headquartered in Malvern, Pennsylvania, continues to advance buntanetap toward potential regulatory submission, with the goal of providing a disease-modifying treatment that could significantly impact patients’ lives.

The full press release is available at https://ibn.fm/M77X4. For more information about Annovis, visit their website at www.annovisbio.com and follow them on social media. InvestorWire, a specialized communications platform, distributed this news as part of its services to enhance visibility for public and private companies. The Dynamic Brand Portfolio @ IBN includes InvestorWire, which offers press release syndication, editorial distribution to 5,000+ outlets, and social media reach. For more details, visit InvestorWire.